Point72 DIFC Ltd Purchases Shares of 6,987 Cabaletta Bio, Inc. (NASDAQ:CABA)

Point72 DIFC Ltd purchased a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 6,987 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently modified their holdings of CABA. Point72 Asset Management L.P. acquired a new stake in shares of Cabaletta Bio in the third quarter valued at about $3,150,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Cabaletta Bio in the third quarter valued at approximately $32,000. Fred Alger Management LLC grew its stake in Cabaletta Bio by 63.3% in the third quarter. Fred Alger Management LLC now owns 4,119,394 shares of the company’s stock valued at $19,444,000 after purchasing an additional 1,596,512 shares in the last quarter. Walleye Capital LLC increased its position in shares of Cabaletta Bio by 111.6% during the 3rd quarter. Walleye Capital LLC now owns 401,982 shares of the company’s stock worth $1,897,000 after purchasing an additional 212,025 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Cabaletta Bio by 6.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 125,845 shares of the company’s stock worth $594,000 after purchasing an additional 7,518 shares in the last quarter.

Analyst Upgrades and Downgrades

CABA has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Cabaletta Bio in a report on Friday, November 15th. William Blair restated an “outperform” rating on shares of Cabaletta Bio in a research note on Monday, November 18th. UBS Group started coverage on shares of Cabaletta Bio in a research note on Thursday, October 10th. They issued a “buy” rating and a $10.00 target price for the company. Evercore ISI lowered their price target on Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Finally, Wells Fargo & Company cut their price objective on Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Cabaletta Bio currently has an average rating of “Buy” and an average price target of $26.25.

Cabaletta Bio Trading Down 5.8 %

NASDAQ:CABA opened at $3.11 on Tuesday. The stock has a 50 day simple moving average of $3.79 and a 200 day simple moving average of $5.82. The stock has a market cap of $152.01 million, a P/E ratio of -1.45 and a beta of 2.37. Cabaletta Bio, Inc. has a 1-year low of $1.76 and a 1-year high of $26.35.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.